ABSTRACT
Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations.
Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri).
Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively.
Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly.
HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
Funding was provided by the US Food and Drug Administration.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The US Department of Health and Human Services Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDAs Sentinel Initiative. We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. Using Medicare data for this surveillance activity is permitted under the HIPAA Privacy Rule for public health practice without individual authorization. Furthermore, public health surveillance activities including this study are not subject to the Common Rule as verified in the OHRP letter. Therefore, this study as a public health surveillance activity within the Sentinel Initiative was exempt from an IRB review and approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U. S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States
Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States
Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Mail Stop B3-30-03, Baltimore, Maryland 21244-1850, United States
Author Email Addresses: Azadeh Shoaibi (Azadeh.Shoaibi{at}fda.hhs.gov), Patricia C. Lloyd (Patricia.Lloyd{at}fda.hhs.gov), Hui-Lee Wong (Huilee.Wong{at}fda.hhs.gov), Tainya C. Clarke (Tainya.Clarke{at}fda.hhs.gov), Yoganand Chillarige (ychillarige{at}acumenllc.com), Rose Do (rdo{at}acumenllc.com), Mao Hu (mhu{at}acumenllc.com), Yixin Jiao (yjiao{at}acumenllc.com), Andrew Kwist (akwist{at}acumenllc.com), Arnstein Lindaas (alindaas{at}acumenllc.com), Rowan McEvoy (rmcevoy{at}acumenllc.com), Michelle Ondari (mondari{at}acumenllc.com), Shruti Parulekar (sparulekar{at}acumenllc.com), Xiangyu Shi (xshi{at}acumenllc.com), Jing Wang (jwang{at}acumenllc.com), Yun Lu (Yun.Lu{at}fda.hhs.gov), Joyce Obidi (Joyce.Obidi{at}fda.hhs.gov), Cindy K. Zhou (cindy.ke.zhou{at}gmail.com), Jeffrey A. Kelman, Richard A. Forshee (Richard.Forshee{at}fda.hhs.gov), Steven A. Anderson (Steven.Anderson{at}fda.hhs.gov)
Conflict of Interest Statement Co-authors from U.S. Food and Drug Administration, Acumen LLC, and Centers for Medicare & Medicaid Services declared no conflicts of interests.
Data Availability
All data described in the present study is not available to protect patient confidentiality.
